Phase 3 Study of Ripasudil (K-321) Eye Drops in Patients with Fuchs Endothelial Corneal Dystrophy

This 72-week study is testing a new eye injection (BI 764524) to see if it can safely slow or improve diabetic eye disease in people with moderate to severe non-proliferative diabetic retinopathy.

This UK study is testing whether a vitamin (nicotinamide) can help protect vision in people with glaucoma when added to standard eye pressure treatments.

This study is testing a new eye surgery for macular holes that avoids gas bubbles and face-down recovery, aiming to make healing easier and safer.

This study compares two surgeries for retinal detachment: one that fixes the retina and removes the lens at the same time, and one that delays lens removal until needed.

This study uses advanced eye scans to track healing after glaucoma surgery and spot early signs of failure, which can lead to vision loss.

This study is creating a UK-wide registry to track outcomes of a laser treatment for glaucoma (MPTLT), aiming to provide strong evidence of how well it works.

This Phase 3 study is testing a one-time gene therapy (RGX-314) for wet age-related macular degeneration (AMD), aiming to reduce or eliminate the need for frequent eye injections.

This study is testing whether a simpler injection schedule (“Light Touch”) for a new eye drug (faricimab) works just as well as the standard approach in people with wet AMD.

This study is testing a new laser-activated drug (bel-sar) for treating small eye tumors (IL/CM) to see if it safely slows or stops their growth.

This study is testing whether a newer, quicker eye scan (OCTA) can reliably diagnose wet age-related macular degeneration (nAMD), instead of using older dye-based tests.

This study compares two treatments for severe diabetic macular oedema: ongoing eye injections alone, or injections followed by a gentle laser once swelling improves.

This  study is testing how well and how safely the drug faricimab works when given as few as once every 24 weeks in people with neovascular (wet) age-related macular degeneration. The study will compare two treatment approaches to see how long the drug’s effects last and how it impacts patients’ vision over time.